Effects of local and systemic Atorvastatin on inflammation and alveolar bone loss in experimental periodontitis in rats
Journal of Dental School,
Vol. 35 No. 4 (2017),
27 October 2017
,
Page 127-132
https://doi.org/10.22037/jds.v35i4.24593
Abstract
Objectives The first cause of tooth loss in developed countries is periodontitis and mostly occurs in people over 40 years old.Atorvastatin is a statin drug class, which has a revolutionary impact on the treatment of high cholesterol and also stimulates bone morphogenic protein which has osteogenic potential. The aim of this study was to evaluate the effect of local and systemic Atorvastatin in the treatment of periodontitis.
Materials and Methods Forty eight Sprague Dawley rats were randomly divided into six groups of eight in each; experimental periodontitis was induced by ligature in five of them in each group daily (1) systemic Atorvastatin 12.5 mg/kg (2) systemic solvent (3) local Atorvastatin
0.25 mg/kg (4) local solvent (5) no drug was administered and group (6) left non-ligated, and rats were sacrificed on 11th day. Histopathological analysis on periodontal tissue; malondialdehyde (MDA) and superoxide dismutase (SOD) tests on serum were performed to investigate bone loss and inflammation. The statistical tests for MDA and SOD samples were one-way ANOVA with Duncan post-hoc whereas in histopathological samples nonparametric Kruskal–Wallis and Mann–Whitney tests were used.
Results Although local injection and oral administration of Atorvastatin significantly decreased alveolar bone loss and serum MDA levels, no significant difference in their effectiveness was observed. Serum SOD levels were not significantly changed in all administered groups. P-value < 0.05.
Conclusion In this study, both local injection and oral forms of Atorvastatin decreased inflammation and bone loss in periodontitis. However, no significant difference in their effectiveness was detected. However, local injection is superior to oral form due to effective lower dose.- atorvastatin
- histopathology
- periodontal disease
- rat
How to Cite
References
Cafiero C, Matarasso M, Marenzi G, Iorio Siciliano V, Bellia L, Sammartino G. Periodontal aare as a fundamental step for an fctive and healthy ageing. Sci World J. 2013;17:127905.
Oliver RC, Brown LJ, LÃ H. Periodontal diseases in the United States population. J Periodontol. 1998;69:269–278.
Kinane DF, Shiba H, Hart TC. The genetic basis of periodontitis. Periodontol. 2000. 2005;39:91–117.
Ismail G, Dumitriu HT, Dumitriu AS, Ismail FB. Periodontal disease: A covert source of inflammation in chronic kidney disease patients. Int J Nephrol. 2013;2013:5796.
Subramanian S, Emami H, Vucic E, Singh P, Vijayakumar J, Fifer KM, et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J Am Coll Cardiol. 2013;62:2382–2391.
Tonetti MS, D’Aiuto F, Nibali L, Donald A, Storry C, Parkar M, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356:911–920.
Figuero E, Sánchez-Beltrán M, Cuesta-Frechoso S, Tejerina JM, del Castro JA, Gutiérrez JM, et al. Detection of periodontal bacteria in atheromatous plaque by nested polymerase chain reaction. J Periodontol. 2011;82:1469–1477.
de Araújo Júnior RF, Souza TO, de Moura LM, Torres KP, de Souza LlB, Alves Mdo S, et al. Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis. PloS one. 2013;10:e75322.
Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis. 2004;177:161–166.
Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, Kobayashi N, et al. Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure. J Cardiol. 2012;59:374–382.
Nassar CA, Battistetti GD, Nahsan FP, Olegário J, Marconato J, Marin CF, et al. Evaluation of the effect of simvastatin on the progression of alveolar bone loss in experimental periodontitis—an animal study. J Int Acad Periodontol. 2014;16:2–7.
Balli U, Keles GC, Cetinkaya BO, Mercan U, Ayas B, Erdogan D. Assessment of vascular endothelial growth factor and matrix metalloproteinase-9 in the periodontium of rats treated with atorvastatin. J Periodontol. tol. 2014;85:178–187.
Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res. 2004;43:200–227.
Chang B, Yang J, Li H, Lu S, Chen L, Fang P. Effects of atorvastatin on bone metabolism and bone mineral density in Wistar rats. Pharmazie. 2011;66:535–537.
Lima MDR, Lopes AP, Martins C, Brito GAC, Carneiro VC, Goes P. The effect of Calendula officinalis on oxidative stress and bone loss in experimental periodontitis. Front Physiol. 2017;8:440.
Bertl K, Parllaku A, Pandis N, Buhlin K, Klinge B, Stavropoulos A. The effect of local and systemic statin use as an adjunct to non-surgical and surgical periodontal therapy—A systematic review and metaanalysis. J Dent. 2017; 67:18–28.
Sinjab K, Zimmo N, Lin GH, Chung MP, Shaikh L, Wang HL. The effect of locally delivered statins on treating periodontal intrabony defects: a systematic review and meta-analysis. J Periodontol. 2017;88:357–367.
Akram Z, Vohra F, Javed F. Efficacy of statin delivery as an adjunct to scaling and root planing in the treatment of chronic periodontitis: a meta-analysis. J Investig Clin Dent. 2017;e12304.
19. Holzhausen M, Rossa Júnior C, Marcantonio Júnior E, Nassar PO, Spolidorio DM, Spolidorio LC. Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats. J Periodontol. 2002;73:1030-6.
Vardar S, Baylas H, Huseyinov A. Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and prostaglandin F2 and clinical parameters of chronic periodontitis. J Periodontol. 2003;74:57–63.
Estanislau IM, Terceiro IR, Lisboa MR, Teles Pde B, Carvalho Rde S, Martins RS, et al. Pleiotropic effects of statins on the treatment of chronic periodontitis—A systematic review. Br J Clin Pharmacol. 2015;79:877–885.
Maher BM, Dhonnchu TN, Burke JP, Soo A, Wood AE, Watson RW. Statins alter neutrophil migration by modulating cellular Rho activity—A potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol. 2009;85:186–193.
- Abstract Viewed: 251 times
- PDF Downloaded: 169 times